trial · primary record
Olaparib
Recurrent Head and Neck Squamous Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2028-10-31 |
| Primary endpoint | Objective Response Rate (ORR) as Assessed by RECIST v1.1 |
| Registry ID | NCT04643379 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:10.754Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04643379
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.